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To the Editor,
There remain a number of uncertainties globally about the 
risks posed to women who are infected with SARS-CoV-2 dur-
ing pregnancy, in particular, whether COVID-19 increases 
the risk of adverse outcomes for mother and baby, and the 
ways in which the virus or immunity to the virus may be 
passed from the pregnant woman or breastfeeding mother 
to her infant. Much of the strongest evidence published 
thus far has been in the form of systematic reviews and 
meta-analyses of observational data [1–3], and little has 
been published on this topic from Africa to date.
There have been a number of registries set up interna-
tionally to capture data from women who have been diag-
nosed with COVID-19 during pregnancy, many of which 
have been instrumental in providing crucial observational 
data about pregnancy outcomes in this cohort. These data 
are, however, limited in that they do not provide sufficient 
insight into the mechanisms underlying the observed out-
comes, highlighting a need for the collection of clinical 
samples in this context.
Recently-published data have also suggested that 
symptomatic women may represent only the tip of the ice-
berg of SARS-CoV-2 infection in pregnancy [4, 5], making 
it possible that registries contain data from only a small 
proportion of true SARS-CoV-2 positive cases, especially in 
countries where mass testing has not yet been adopted. 
It is therefore imperative that asymptomatic pregnant 
women are also screened for the virus in order to capture 
the full breadth of effects of SARS-CoV-2 infection in both 
pregnancy and infancy.
PeriCOVID Africa plans to address these knowledge gaps 
by harnessing the infrastructures already in place for a 
number of large studies in sub-Saharan Africa, including 
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There remain a number of uncertainties globally about the risks posed to women who are infected 
with SARS-CoV-2 during pregnancy. Furthermore, our understanding of the spread of COVID-19 in 
 Sub-Saharan Africa is limited, owing to low testing rates in many parts of the continent. PeriCOVID 
Africa, in  conjunction with the WHO/HRP Alliance, plans to address these knowledge gaps by harness-
ing research infrastructures in place in five sub-Saharan African countries in order to screen more than 
50,000 pregnant women and their infants for SARS-CoV-2, while monitoring pregnancy and neonatal 
outcomes. We anticipate that the results of this study will provide much needed information about the 
risks that SARS-CoV-2 poses to pregnant women and their babies, as well as establishing potential routes 
of mother-to-child transmission.
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PREPARE, PRECISE, BAMBI II and the “Early versus late 
BCG vaccination in HIV-1 exposed infants in Uganda” ran-
domised controlled trial. This platform will screen more 
than 59,000 pregnant women for SARS-CoV-2 infection 
and collect clinical samples and data from mothers and 
babies among a birth cohort of nearly 100,000 women 
and infants in the Gambia, Kenya, Malawi, Mozambique 
and Uganda, with additional data from collaborators in 
South Africa (Figure 1).
This body of work will be carried out in conjunction 
with the World Health Organisation (WHO) and the 
United Nations Development Program (UNDP)-United 
Nations Population Fund (UNFPA)-UNICEF-WHO-World 
Bank Special Program of Research, Development and 
Research Training in Human Reproduction, known as the 
HRP Alliance, who together hosted COVID-19 and preg-
nancy research working group meetings which brought 
together global expertise, enabling the development a 
generic cohort protocol addressing COVID-19 among 
pregnant women and their neonates.
Over a 12-month period, we will collect throat swabs 
(to test for SARS-CoV-2 RNA) and blood samples (for 
SARS-CoV-2 serology [IgM/IgG]) from pregnant women 
presenting for antenatal care at our designated study 
sites, based in primary health care facilities and govern-
ment hospitals in each of the five countries. In align-
ment with the WHO/HRP Alliance’s generic cohort 
protocol, we will then follow these women until delivery 
where we will take further samples including cord blood 
and nasal swabs from the infants to assess for evidence 
of vertical transmission, and will also collect clinical 
data from all enrolled women to determine the rela-
tive risk of adverse outcomes in women who test posi-
tive for SARS-CoV-2 during pregnancy. All data collected 
will be integrated into existing registries and reported 
monthly to the WHO/HRP Alliance-designated platform 
so that important results can be widely disseminated in 
real-time.
We anticipate that the results of this study will help 
provide the first vital steps to understanding the 
pathophysiology of the risks that SARS-CoV-2 poses to 
pregnant women and their babies, as well as establishing 
potential routes of mother-to-child transmission, which 
will inform infection prevention and control measures 
recommended for pregnant and breastfeeding women.
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